+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2019 Respiratory Syncytial Virus (RSV) Infections Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025

  • ID: 4768000
  • Report
  • April 2019
  • Region: Global
  • 153 pages
  • VPA Research

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc
  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
The global clinical trial report- “2019 Respiratory Syncytial Virus (RSV) Infections Clinical Trials Study” provides complete list of trials completed, ongoing and planned for Respiratory Syncytial Virus (RSV) Infections. It presents in-depth analysis of Respiratory Syncytial Virus (RSV) Infections clinical trials across markets and companies. The research work is for providing complete understanding into trends in Respiratory Syncytial Virus (RSV) Infections.

The report covers a key snapshot of trial trends, enrollment trends, success trends, locations and other trends.

It also segments the Respiratory Syncytial Virus (RSV) Infections clinical trials by:
  • Current Trial Status
  • Type of the trial
  • Sponsor Type
  • Enrollment Trends
  • Region
  • Countries
  • Trial Phase
The report also identifies the potential drug candidates under development for treatment of Respiratory Syncytial Virus (RSV) Infections

The research work is prepared through extensive and continuous research on Respiratory Syncytial Virus (RSV) Infections trials from over 1500 sources including company websites, conferences and presentations, scientific journals, country wise and global clinical trial registries, news, health and science departments among others.

Report Scope and Coverage:
  • All major trials from 2010 to 2019 and planned trials are included in the report scope.
  • Drug candidates currently being researched for administering Respiratory Syncytial Virus (RSV) Infections patients are identified
  • The report includes panorama of Respiratory Syncytial Virus (RSV) Infections clinical trials across the globe
  • Trial Phase, Current Status, Sponsor Type, Location, trial type and Enrollment details are provided
  • Companies and universities focusing on Respiratory Syncytial Virus (RSV) Infections clinical trials are analyzed along with their trial participation (trial title, trial phase and current status)
  • Average Enrollment number, insights into enrollment trends, company wise enrollment are included
  • Both interventional and observational studies are analyzed
  • News and latest developments for the past one year are presented in the report
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc
  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
1.1 List of Figures
1.2 List of Tables

2. Executive Summary
2.1 Respiratory Syncytial Virus (RSV) Infections Clinical Trials Overview, 2019
2.2 Premium Insights into Clinical Trials
2.2.1 Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Region
2.2.2 Average Enrollment of Respiratory Syncytial Virus (RSV) Infections Clinical Trials
2.2.3 Companies participating in Trials
2.2.4 Drugs under Study for Respiratory Syncytial Virus (RSV) Infections Treatment, 2019

3. Region wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials
3.1 Asia Pacific Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Country
3.2 Europe Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Country
3.3 North America Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Country
3.4 Middle East and Africa Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Country
3.5 South and Central America Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Country

4. Respiratory Syncytial Virus (RSV) Infections Clinical Trial Trends
4.1 Start Year wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials
4.2 Phase wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials
4.3 Trial Status wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials
4.4 Trial Type wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials

5. Respiratory Syncytial Virus (RSV) Infections Average Enrollment Trends
5.1 Average Enrollment in Respiratory Syncytial Virus (RSV) Infections Trials by Year
5.2 Average Enrollment in Respiratory Syncytial Virus (RSV) Infections Trials by Phase
5.3 Average Enrollment in Respiratory Syncytial Virus (RSV) Infections Trials by Status
5.4 Average Enrollment in Respiratory Syncytial Virus (RSV) Infections Trials by Type of Trial

6. Companies Participating in Respiratory Syncytial Virus (RSV) Infections Clinical Trials
6.1 Respiratory Syncytial Virus (RSV) Infections Trials by Sponsor Type
6.2 Respiratory Syncytial Virus (RSV) Infections Average Enrollment by Sponsor Type
6.3 Subjects Recruited by Leading Sponsors

7. Trial Snapshots- Phase, Type, Title, Location, Start Year, Completion Year, Recruitment Status, Enrollment, Participating Countries, Trial Locations, Company, Drugs and Other Details
7.1 Respiratory Syncytial Virus (RSV) Infections Trials- Phase 1
7.2 Respiratory Syncytial Virus (RSV) Infections Trials- Phase 2
7.3 Respiratory Syncytial Virus (RSV) Infections Trials- Phase 3
7.4 Respiratory Syncytial Virus (RSV) Infections Trials- Phase 4

8. Appendix
8.1 Report Guidance
8.2 Research Methodology
8.3 Abbreviations
8.4 Definitions
8.5 Sources
8.6 Publisher Expertise

List of Figures
Figure 1: Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Region, 2019
Figure 2: Country wise Clinical Trials, 2019
Figure 3: Country wise Average Enrolment, 2019
Figure 4: Asia Pacific - Country wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials and Enrolment
Figure 5: Europe - Country wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials and Enrolment
Figure 6: Middle East Africa - Country wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials and Enrolment
Figure 7: North America - Country wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials and Enrolment
Figure 8: South and Central America - Country wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials and Enrolment
Figure 9: Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Phase
Figure 10: Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Trial Status
Figure 11: Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Type
Figure 12: Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Sponsor Type
Figure 13: Respiratory Syncytial Virus (RSV) Infections Clinical Trials by Leading Sponsors
Figure 14: Respiratory Syncytial Virus (RSV) Infections Average Enrollment by Phase
Figure 15: Respiratory Syncytial Virus (RSV) Infections Average Enrollment by Trial Status
Figure 16: Respiratory Syncytial Virus (RSV) Infections Average Enrollment by Type
Figure 17: Respiratory Syncytial Virus (RSV) Infections- Average Enrolment by Type of Sponsors
Figure 18: Respiratory Syncytial Virus (RSV) Infections- Enrolment by Leading Sponsors
Figure 19: Research Methodology

List of Tables
Table 1: Respiratory Syncytial Virus (RSV) Infections Clinical Trials Snapshot- 2019
Table 2: Trials by Region, 2019
Table 3: Country wise Clinical Trials and Average Enrolment by Country, 2019
Table 4: Asia Pacific - Country wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials and Enrolment
Table 5: Europe - Country wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials and Enrolment
Table 6: Middle East Africa - Country wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials and Enrolment
Table 7: North America - Country wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials and Enrolment
Table 8: South and Central America - Country wise Respiratory Syncytial Virus (RSV) Infections Clinical Trials and Enrolment
Table 9: Clinical Trials by Phase
Table 10: Clinical Trials by Trial Status
Table 11: Clinical Trials by Type
Table 12: Clinical Trials by Sponsor Type
Table 13: Clinical Trials by Leading Sponsors
Table 14: Respiratory Syncytial Virus (RSV) Infections Average Enrollment by Phase
Table 15: Respiratory Syncytial Virus (RSV) Infections Average Enrollment by Trial Status
Table 16: Respiratory Syncytial Virus (RSV) Infections Average Enrollment by Type
Table 17: Respiratory Syncytial Virus (RSV) Infections- Average Enrolment by Type of Sponsors
Table 18: Respiratory Syncytial Virus (RSV) Infections- Enrolment by Leading Sponsors
Note: Product cover images may vary from those shown
  • Abbott Laboratories
  • AbbVie Inc
  • Alnylam Pharmaceuticals Inc
  • AstraZeneca Plc
  • Bavarian Nordic A/S
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Novavax Inc
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll